Cytokinetics (CYTK) The Citizens Life Sciences Conference 2026 summary

Clinical trial updates and market opportunity

• ACACIA-HCM Phase III trial results for Myqorzo in non-obstructive HCM are expected in Q2, targeting a patient population representing about 50% of diagnosed HCM cases in the US.

• Myqorzo is already approved for obstructive HCM, with an estimated 100,000 eligible US patients; a similar number is anticipated for non-obstructive HCM.

• If ACACIA is positive and FDA-approved, Myqorzo could be the only approved therapy for NHCM, expanding its market beyond OHCM.

• The ODYSSEY-HCM trial for Camzyos in NHCM was a near miss, but differences in trial design and conduct give optimism for ACACIA's success.

• Success in ACACIA could inform future development for heart failure with preserved ejection fraction (HFpEF), a much larger population.

Scientific rationale and trial design

• Both OHCM and NHCM share disease mechanisms, including heart thickening and diastolic dysfunction, making cardiac myosin inhibitors relevant for both.

• Phase II studies for Myqorzo in NHCM focused on dosing strategy, using maximum tolerated dose due to the absence of a gradient in NHCM.

• ACACIA uses a straightforward titration protocol, allowing patients to reach target dose within six weeks and maintain it for 30 weeks before endpoint assessment.

• Lessons from ODYSSEY-HCM informed ACACIA’s design, avoiding pitfalls like high placebo effects and inconsistent dosing.

• Consistent team, core lab oversight, and rigorous patient screening are emphasized as key to successful trial conduct.

Product differentiation and launch strategy

• Myqorzo was engineered for a gradual exposure-response, minimal drug interactions, and flexible dosing, enhancing safety and ease of use.

• FDA approval included a REMS program with less burdensome monitoring and greater convenience for physicians and patients.

• Early launch metrics are positive: over 700 cardiologists completed REMS training, high awareness, and rapid patient reimbursement.

• Uptake includes prescribers new to the cardiac myosin inhibitor class, suggesting broader market penetration.

• The company aims to expand from core prescribers to the wider cardiology community, targeting 8,000–10,000 potential prescribers.